CA1170991A - Products prepared from the serum thymic factor or its analogs and derivatives, a process for preparing these products, the use of these products as medicaments, tracers obtained from these products and the use of these tracers in detection processes - Google Patents
Products prepared from the serum thymic factor or its analogs and derivatives, a process for preparing these products, the use of these products as medicaments, tracers obtained from these products and the use of these tracers in detection processesInfo
- Publication number
- CA1170991A CA1170991A CA000378037A CA378037A CA1170991A CA 1170991 A CA1170991 A CA 1170991A CA 000378037 A CA000378037 A CA 000378037A CA 378037 A CA378037 A CA 378037A CA 1170991 A CA1170991 A CA 1170991A
- Authority
- CA
- Canada
- Prior art keywords
- metal
- fts
- products
- ser
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C07K7/062—Serum thymic factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8017027 | 1980-05-22 | ||
GB8017027 | 1980-05-22 | ||
GB8030507 | 1980-09-22 | ||
GB8030507 | 1980-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1170991A true CA1170991A (en) | 1984-07-17 |
Family
ID=26275622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000378037A Expired CA1170991A (en) | 1980-05-22 | 1981-05-21 | Products prepared from the serum thymic factor or its analogs and derivatives, a process for preparing these products, the use of these products as medicaments, tracers obtained from these products and the use of these tracers in detection processes |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0041019B1 (enrdf_load_stackoverflow) |
AU (1) | AU553640B2 (enrdf_load_stackoverflow) |
CA (1) | CA1170991A (enrdf_load_stackoverflow) |
DE (1) | DE3166925D1 (enrdf_load_stackoverflow) |
DK (1) | DK221681A (enrdf_load_stackoverflow) |
ES (2) | ES8306022A1 (enrdf_load_stackoverflow) |
GR (1) | GR75636B (enrdf_load_stackoverflow) |
IE (1) | IE51744B1 (enrdf_load_stackoverflow) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634682A (en) * | 1982-11-30 | 1987-01-06 | Sloan-Kettering Institute For Cancer | Radioimmunoassays for the serum thymic factor (FTS) |
CS256897B1 (en) * | 1984-12-17 | 1988-04-15 | Evzen Kasafirek | Series thymic factor's analogue-type peptides |
IT1188550B (it) * | 1986-02-07 | 1988-01-14 | Sclavo Spa | Peptide sintetico ad attivita' interleukina 1 umana |
FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
WO2007108848A1 (en) | 2006-03-20 | 2007-09-27 | Smith & Nephew, Inc. | Acetabular cup assembly for multiple bearing materials |
FR2930156B1 (fr) * | 2008-04-21 | 2011-10-28 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes. |
WO2021030689A2 (en) * | 2019-08-15 | 2021-02-18 | Cytolyf Therapeutics Llc | Zinc activated thymulin and methods of preparation and administration |
-
1981
- 1981-05-20 GR GR65000A patent/GR75636B/el unknown
- 1981-05-20 DK DK221681A patent/DK221681A/da not_active Application Discontinuation
- 1981-05-21 AU AU70905/81A patent/AU553640B2/en not_active Ceased
- 1981-05-21 DE DE8181400807T patent/DE3166925D1/de not_active Expired
- 1981-05-21 IE IE113581A patent/IE51744B1/en not_active IP Right Cessation
- 1981-05-21 CA CA000378037A patent/CA1170991A/en not_active Expired
- 1981-05-21 EP EP19810400807 patent/EP0041019B1/fr not_active Expired
- 1981-05-22 ES ES502911A patent/ES8306022A1/es not_active Expired
-
1982
- 1982-12-16 ES ES518298A patent/ES518298A0/es active Granted
Also Published As
Publication number | Publication date |
---|---|
GR75636B (enrdf_load_stackoverflow) | 1984-08-02 |
EP0041019A3 (en) | 1982-03-10 |
ES502911A0 (es) | 1983-05-01 |
DK221681A (da) | 1981-11-23 |
EP0041019B1 (fr) | 1984-10-31 |
AU553640B2 (en) | 1986-07-24 |
IE811135L (en) | 1981-11-22 |
AU7090581A (en) | 1981-11-26 |
IE51744B1 (en) | 1987-03-18 |
ES8501628A1 (es) | 1984-12-16 |
EP0041019A2 (fr) | 1981-12-02 |
DE3166925D1 (en) | 1984-12-06 |
ES8306022A1 (es) | 1983-05-01 |
ES518298A0 (es) | 1984-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brown et al. | Bombesin-like activity: radioimmunologic assessment in biological tissues | |
Olsen | Morphine binding to human plasma proteins | |
Tarrab-Hazdai et al. | Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. | |
Martin et al. | Experimental production of sheep pulmonary adenomatosis (Jaagsiekte) | |
Waldmann et al. | The metabolism of IgE: studies in normal individuals and in a patient with IgE myeloma | |
Yachnin et al. | Inhibition of human lymphocyte transformation by human alpha-foetoprotein (HAFP); comparison of foetal and hepatoma HAFP and kinetic studies in vitro immunosuppression | |
Gulati et al. | Role of ET and NO in resuscitative effect of diaspirin cross-linked hemoglobin after hemorrhage in rat | |
Cooper et al. | In vivo release of glycoprotein I from the Ha subline of TA3 murine tumor into ascites fluid and serum | |
EP0288959A2 (en) | Novel glycoprotein, production process thereof and immunosuppressive agent containing same as effective ingredient | |
Viana et al. | Antinociceptive activity of sulfated carbohydrates from the red algae Bryothamnion seaforthii (Turner) Kütz. and B. triquetrum (SG Gmel.) M. Howe | |
Gregory et al. | Luteinizing hormone release from dissociated pituitary cells by dimerization of occupied LHRH receptors | |
Pick et al. | Release of skin reactive factor from guinea-pig lymphocytes by mitogens | |
CA1170991A (en) | Products prepared from the serum thymic factor or its analogs and derivatives, a process for preparing these products, the use of these products as medicaments, tracers obtained from these products and the use of these tracers in detection processes | |
Borek et al. | Immunogenicity and role of size: response of guinea pigs to oligotyrosine and tyrosine derivatives | |
US5616685A (en) | snRNP-A antigen and fragments thereof | |
US4680276A (en) | Metal polypeptides | |
Twardzik et al. | Comparison of growth factors functionally related to epidermal growth factor in the urine of normal and human tumor-bearing athymic mice | |
Praissman et al. | Modification of the C-terminal octapeptide of cholecystokinin with a high-specific-activity lodinated imidoester: Preparation, characterization, and binding to isolated pancreatic acinar cells | |
Lester et al. | Inhibition of human lymphocyte transformation by human alpha-foetoprotein (HAFP): studies on the mode of HAFP action and the role of HAFP polymorphism | |
HIRSHORN et al. | Carcinoma of the breast associated with hypercalcemia and the presence of parathyroid hormone-like substances in the tumor | |
Brand et al. | Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-α subtypes | |
CN115073553B (zh) | 一种选择性tnfr1拮抗肽sn61-4g及其在炎症性肠病中的应用 | |
Yodoi et al. | Formation of IgE-binding factors by rat T lymphocytes. I. Induction of IgE-binding factors by poly I: C and interferon. | |
Bernard et al. | Inhibition by serum of encephalitogenic activity of myelin basic protein: nature of the serum factor responsible | |
Laburthe et al. | Glucagon and insulin from lean rats and genetically obese fatty rats: studies by radioimmunoassay, radioreceptorassay and bioassay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |